Cervical Glandular Neoplasm

subtype

Identifier: CI-CAN-00000663
Entity page: /cancer/cervical-glandular-neoplasm ↗
Edges: 567

Neighbours: 200 genes15 drugs10 trials
Drawn: 60 of 225 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Cervical Glandular Neoplasm altered in cohorts of …ALTERED_INderived200 of 200show fewer
← altered in cohorts of	PTEN 194 / 247 cases (79 %) · ssm · uec_cptac_gdc	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ARID1A 136 / 247 cases (55 %) · ssm · uec_cptac_gdc

Cervical Glandular Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 82show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

48 trials (15 active) · roll-up of the cancer and its descendants

—

Cervical Glandular Neoplasm

Observed

Cervical Glandular Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 82show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 48 trials (15 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 34 trials (11 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 33 trials (7 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 31 trials (12 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 16 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 13 trials (2 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 12 trials (6 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 12 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 11 trials (9 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 11 trials (8 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 9 trials (2 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 8 trials (4 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 7 trials (5 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 6 trials (6 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Cervical Glandular Neoplasm	6	Observed	clinicaltrials	graph →

Cervical Glandular Neoplasm studied in …STUDIED_INderived10 of 285show all (up to 200)
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 285 trials mapped (103 active)	—	—	Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 285 trials mapped (103 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 285 trials mapped (103 active)	—	—	Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 285 trials mapped (103 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 285 trials mapped (103 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 285 trials mapped (103 active)	—	—	Cervical Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 285 trials mapped (103 active)	—	—	Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 285 trials mapped (103 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07078838Phase 2 · not yet recruiting Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer · condition mapped ALIAS · 285 trials mapped (103 active)	—	—	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06084780Phase 2 · not yet recruiting Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) · condition mapped ONTOLOGY_EXACT · 285 trials mapped (103 active)	—	—	Pseudomyxoma Peritonei	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains